

X-ray Crystal Structure of ERK5 (MAPK7) in Complex with a Specific Inhibitor

Jonathan M. Elkins, Jing Wang, Xianming Deng, Michael J. Pattison, J. Simon C. Arthur, Tatiana Erazo, Nestor Gomez, Jose M. Lizcano, Nathanael S. Gray and Stefan Knapp


Supplementary Information

Contents

Supplementary Figure 1.....	2
Supplementary Figure 2.....	3
Supplementary Figure 3.....	4
Supplementary Figure 4.....	5
Supplementary Figure 5.....	6
Supplementary Figure 6.....	Error! Bookmark not defined.
ERK5 Protein Sequences used for crystallisation.....	7

Supplementary Figure 1


Interaction of the inhibitor **25** (in yellow) with two other ERK5 molecules in the crystal lattice. The symmetry-related ERK5 molecules are shown in purple (1st molecule), and green and pink (2nd molecule, activation loop in pink).




Supplementary Figure 2

Charged surface comparison of ERK5 with the complex between ERK2 and a DUSP6 (MKP3) Kinase Interaction Motif (KIM) docking peptide (PDB ID 2FYS) (Liu S. et al., PNAS, 2006, 103, 5326-5331). The KIM peptide in the ERK2 structure is shown in green, and the inhibitor in the ERK5 structure is shown in yellow. Scale in electronvolts.

ERK5




front




back

ERK2 with DUSP6 (MKP3) KIM peptide



front




back






Supplementary Figure 3

Activation of ERK5 by active MEK5 (MEK5DD) induces AP1 transcriptional activity. The pAP1-luciferase reporter and pRL-CMV-Renilla plasmids were co-transfected with plasmids encoding for the indicated proteins and 24 h later lysates were subjected to the dual-luciferase assay. Each value is the mean \pm s.d. of four different determinations, each performed in triplicate, and normalized using the Renilla values.



Supplementary Figure 4


EC₅₀ for **24** (ERK5-mediated AP-1 transcriptional activity assay).



Compound 24 EC₅₀ >30 μM

Supplementary Figure 5

Sequence alignment of the N-terminal regions of various kinases relevant for the discussion of inhibitor selectivity for the ERK5-IN-1 inhibitor series.



ERK5 Protein Sequences used for crystallisation

Expressed protein sequence (including His6 tag):

MGHHHHHSSGVDLGTENLYFQSM AEPLKEEDGEDGSAEPPGPVKA EPAHTAASVAAKNLALLKARSFDV
TFDVGDEYEI IETIGNGAYGVVSSARRRLTGQQVAIKKIPNAFDVVTNAKRTLRELKILKHFKHDNIIAI
KDILRPTVPYGEF KSVYVLDLME SDLHQI IHSSQPLTLEHVRYFLYQLLRGLKYM HSAQVIHRDLKPSN
LLVNENCELKIGDFGMARGLCTSPA EHQYFMTEYVATRWRAP ELMLSLHEYTQAIDLWSVGCIFGEMLA
RRQLFP GKNYVHQLQLIMMVLGTPSPAVIQAVGAERV RAYIQSLPPRQPVPWETVYPGADRQALSLLGRM
LRFEPSARI SAAAALRHPFLAKYHDPDDEPDCAPPFDFAFDREALTRERIKEAIVAEIEDFHARREGIRQ

Crystallised protein sequence (after TEV protease digestion):

SMAEPLKEEDGEDGSAEPPGPVKA EPAHTAASVAAKNLALLKARSFDVTFDVGDEYEI IETIGNGAYGVV
SSARRRLTGQQVAIKKIPNAFDVVTNAKRTLRELKILKHFKHDNIIAIKDILRPTVPYGEF KSVYVLDL
MESDLHQI IHSSQPLTLEHVRYFLYQLLRGLKYM HSAQVIHRDLKPSNLLVNENCELKIGDFGMARGLCT
SPA EHQYFMTEYVATRWRAP ELMLSLHEYTQAIDLWSVGCIFGEMLARRQLFP GKNYVHQLQLIMMVLG
TPSPAVIQAVGAERV RAYIQSLPPRQPVPWETVYPGADRQALSLLGRMLRFEPSARI SAAAALRHPFLAK
YHDPDDEPDCAPPFDFAFDREALTRERIKEAIVAEIEDFHARREGIRQ